{"organizations": [], "uuid": "74193d4615d3ddbdad182c58b21ef42cc9544bdc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180130.html", "section_title": "Archive News &amp; Video for Tuesday, 30 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pfizer-reports-q4-eps-of-202/brief-pfizer-reports-q4-eps-of-2-02-idUSASB0C2XL", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer Reports Q4 EPS Of $2.02", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-01-30T19:57:00.000+02:00", "replies_count": 0, "uuid": "74193d4615d3ddbdad182c58b21ef42cc9544bdc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pfizer-reports-q4-eps-of-202/brief-pfizer-reports-q4-eps-of-2-02-idUSASB0C2XL", "ord_in_thread": 0, "title": "BRIEF-Pfizer Reports Q4 EPS Of $2.02", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "negative"}, {"name": "pfizer inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 30 (Reuters) - Pfizer Inc:\n* PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS * Q4 EARNINGS PER SHARE $2.02 * Q4 EARNINGS PER SHARE VIEW $0.56 -- THOMSON REUTERS I/B/E/S\n* QTRLY REVENUE $13,703 MILLION VERSUS $13,627 MILLION * ANTICIPATES REPATRIATION TAX LIABILITY OF APPROXIMATELY $15 BILLION, PAYABLE TO U.S. TREASURY\n* QTRLY INNOVATIVE HEALTH SEGMENT REVENUE $8,218 MILLION VERSUS $7,726 MILLION\n* SEES 2018 REVENUES $53.5 BILLION TO $55.5 BILLION * PROVIDES 2018 FINANCIAL GUIDANCE, INCLUDING REVENUES OF $53.5 TO $55.5 BILLION\n* SEES 2018 ADJUSTED DILUTED EPS $2.90 TO $3.00 * SEES 2018 ADJUSTED RESEARCH AND DEVELOPMENT EXPENSES $7.4 BILLION TO $7.9 BILLION\n* Q4 REVENUE VIEW $13.68 BILLION -- THOMSON REUTERS I/B/E/S\n* PFIZER - OVER NEXT FIVE YEARS, CO PLANS TO INVEST APPROXIMATELY $5.0 BILLION IN CAPITAL PROJECTS IN U.S.\n* FY2018 EARNINGS PER SHARE VIEW $2.78, REVENUE VIEW $53.88 BILLION -- THOMSON REUTERS I/B/E/S\n* PFIZER - ALSO PLANS TO MAKE $500 MILLION CONTRIBUTION TO ITS U.S. PENSION PLAN IN 2018\n* 2018 FINANCIAL GUIDANCE REFLECTS A FULL YEAR CONTRIBUTION FROM CONSUMER HEALTHCARE\n* QTRLY ADJUSTED DILUTED EPS OF $0.62‍​ * CONTINUES TO EXPECT THAT ANY DECISION REGARDING STRATEGIC ALTERNATIVES FOR CONSUMER HEALTHCARE WILL BE MADE DURING 2018\n* PFIZER - ALLOCATED ABOUT $100 MILLION FOR SPECIAL, ONE-TIME BONUS TO BE PAID TO ALL NON-EXECUTIVE COLLEAGUES IN Q1 2018\n* FINANCIAL GUIDANCE FOR 2018 ALSO ASSUMES NO GENERIC COMPETITION FOR LYRICA IN U.S. UNTIL JUNE 2019\n* PFIZER - IN 2018, ANTICIPATES QUARTERLY DIVIDEND PAYMENTS OF $0.34/SHARE OF COMMON STOCK\n* PFIZER - DESPITE ABSORBING $2.1 BILLION IMPACT FROM PRODUCTS THAT LOST MARKETING EXCLUSIVITY, CO WAS STILL ABLE TO ACHIEVE 1% OPERATING. REVENUE GROWTH IN 2017\n* FOURTH-QUARTER 2017 IH OPERATIONAL REVENUE GROWTH WAS NEGATIVELY IMPACTED BY LOWER REVENUES FOR VIAGRA IN U.S.\n* ‍AS A RESULT OF ENACTMENT OF TCJA, Q4 AND FY 2017 PROVISION FOR TAXES ON REPORTED INCOME WAS FAVORABLY IMPACTED BY ABOUT $10.7 BILLION​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-30T19:57:00.000+02:00", "crawled": "2018-01-31T16:11:13.000+02:00", "highlightTitle": ""}